DE69730313D1 - Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer - Google Patents

Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer

Info

Publication number
DE69730313D1
DE69730313D1 DE69730313T DE69730313T DE69730313D1 DE 69730313 D1 DE69730313 D1 DE 69730313D1 DE 69730313 T DE69730313 T DE 69730313T DE 69730313 T DE69730313 T DE 69730313T DE 69730313 D1 DE69730313 D1 DE 69730313D1
Authority
DE
Germany
Prior art keywords
ras
sub
family proteins
compounds therefor
inactivating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730313T
Other languages
English (en)
Other versions
DE69730313T2 (de
Inventor
Eichel-Streiber Christoph Von
Patrice Boquet
Monica Thelestam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Application granted granted Critical
Publication of DE69730313D1 publication Critical patent/DE69730313D1/de
Publication of DE69730313T2 publication Critical patent/DE69730313T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69730313T 1996-02-02 1997-01-31 Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer Expired - Lifetime DE69730313T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96101469 1996-02-02
EP96101469 1996-02-02
PCT/EP1997/000426 WO1997027871A1 (en) 1996-02-02 1997-01-31 Method of inactivation of ras subfamily proteins and agents therefor

Publications (2)

Publication Number Publication Date
DE69730313D1 true DE69730313D1 (de) 2004-09-23
DE69730313T2 DE69730313T2 (de) 2005-09-01

Family

ID=8222454

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730313T Expired - Lifetime DE69730313T2 (de) 1996-02-02 1997-01-31 Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer

Country Status (9)

Country Link
US (1) US6849715B2 (de)
EP (1) EP0877622B1 (de)
AT (1) ATE273712T1 (de)
AU (1) AU1598297A (de)
DE (1) DE69730313T2 (de)
DK (1) DK0877622T3 (de)
ES (1) ES2227667T3 (de)
PT (1) PT877622E (de)
WO (1) WO1997027871A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1675465B1 (de) 2003-10-22 2010-03-03 The Johns Hopkins University Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
WO2005039491A2 (en) * 2003-10-22 2005-05-06 The John Hopkins University Certain improved combination bacteriolytic therapy for the treatment of tumors
US10829752B2 (en) 2014-08-01 2020-11-10 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
WO1994022476A1 (en) * 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants

Also Published As

Publication number Publication date
EP0877622B1 (de) 2004-08-18
EP0877622A1 (de) 1998-11-18
US6849715B2 (en) 2005-02-01
US20030103987A1 (en) 2003-06-05
DE69730313T2 (de) 2005-09-01
ES2227667T3 (es) 2005-04-01
ATE273712T1 (de) 2004-09-15
WO1997027871A1 (en) 1997-08-07
AU1598297A (en) 1997-08-22
PT877622E (pt) 2005-01-31
DK0877622T3 (da) 2004-12-20

Similar Documents

Publication Publication Date Title
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DK0653911T3 (da) Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen
ATE120239T1 (de) System und kontinuierliches verfahren zur biokatalytischen entschwefelung von schwefelhaltigen heterozyklischen molekülen.
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
ES532075A0 (es) Procedimiento para la inactivacion de germenes patogenos, capaces de reproducirse
DE3674941D1 (de) Ozonentkeimung von blut und blutprodukten.
DE69435321D1 (de) Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE58902313D1 (de) Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
DE58904683D1 (de) Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
Adams Regeneration and the kinetics of peroxidase inactivation
DE69730313D1 (de) Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer
ATE106250T1 (de) Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.
DE69308879D1 (de) Methode zur behandlung von abfallverbrennungsrückständen und deren verwendung als adsorptionsmittel
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ES2077707T3 (es) Procedimiento para la inactivacion de la actividad biologica de adn.
ATE205396T1 (de) Verwendung von menschlichem protein c zur verhinderung und behandlung von ablagerungen von thrombocyten
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
DE69730045D1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation
8327 Change in the person/name/address of the patent owner

Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE